Clinical trials: NSCLC Brain Metastasis
NSCLC Patients With Brain Metastasis
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and safety of furmonertinib plus platinum-based doublet chemotherapy (Arm…
- Trial name
- NCT06970639
- Testing
- Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Brain Metastases, Nsclc
The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?
Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life.
- Trial name
- CyberChallenge (NCT05378633)
- Testing
- SRS, Whole Brain Radiotherapy
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- University Hospital Heidelberg
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
This is a prospective, open-label, multi-center, single-arm clinical trial
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
- Trial name
- NCT07343479
- Testing
- sac-TMT plus EGFR-TKI
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhejiang Cancer Hospital
AI (Artificial Intelligence), NSCLC Brain Metastasis
Multimodal Large Model-Driven Risk and Prognosis Assessment for Brain Metastases in Lung Cancer
The goal of this nationwide, multicenter observational study is to develop and externally validate multimodal large models that can (1) predict the risk of brain metastases and (2) estimate long-term prognosis in patients with…
- Trial name
- NCT07107035
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 20,000 people
- Sponsor
- Fudan University
NSCLC, EGFR Activating Mutation
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.
- Conditions
- NSCLC, EGFR Activating Mutation, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT05146219
- Testing
- TY-9591 Tablets
- Where
- China
- Volunteers
- 29 people
- Sponsor
- TYK Medicines, Inc
NSCLC Brain Metastasis
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the…
- Trial name
- NCT06716775
- Testing
- Tumor treating felds (TTF), Best Standard of Care
- Volunteers
- 200 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Non-Small-Cell Lung Cancer (NSCLC), Brain Metastasis
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
Background. During the clinical course of patients with locoregionally advanced non-small-cell lung cancer (LA-NSCLC) who have undergone aggressive treatment, brain metastasis (BM) is a frequent seen pattern of disease relapse…
- Trial name
- NCT02448992
- Testing
- hippocampal-sparing WBRT
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- Chang Gung Memorial Hospital
NSCLC, Brain Metastases
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Conditions
- NSCLC, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT04778800
- Testing
- almonertinib, LM-first line treatment, LM-second line treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital